Breaking through the barrier
Nature Biotechnology
2008년12월22일
A non-invasive method to deliver genes to the central nervous system in mice is reported online this week in Nature Biotechnology. The research could one day lead to new therapies for neurodegenerative disorders such as Lou Gehrig’s disease.
Getting drugs or genes into the brain and spinal cord to treat neurodegenerative diseases is problematic because of the blood?brain barrier (BBB)?a tight wall of cells that restricts the movement of molecules between the blood and neural tissue. Until now, no viruses or viral vectors have been found that cross through the BBB after intravascular injection. Brian Kaspar and colleagues show that a particular strain of virus ? AAV9 ? can be used to carry genes across the BBB in mice and into the brain cells beyond. The team also find that the virus targets cells of the spinal cord and so can be used to deliver genes to widespread regions of the central nervous system.
It is hoped that the technology could one day be used to introduce working copies of the genes that are damaged in diseases such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
doi: 10.1038/nbt.1515
리서치 하이라이트
-
2월18일
Nature Energy Focus issue: How extreme weather events disrupt energy systemsNature Energy
-
1월28일
Materials science: Increased nuclear waste storage corrosion at material interfacesNature Materials
-
1월9일
Ecology: Reassessing impacts of ocean acidification on fish behaviourNature
-
12월20일
Marine biology: Acidified oceans may corrode shark scalesScientific Reports
-
12월19일
Anthropology: The final stand of Homo erectusNature
-
12월17일
Energy: Health and financial impacts of time-of-use energy rates raise equity concernsNature Energy
